drugset / Trial / NCT03701581

4-aminopyridine Treatment for Nerve Injury

NCT03701581

Phase 2/3 Recruiting 70 enrolled John Elfar
RandomizedParallel-groupQuadruple-blindTreatment

Summary

To evaluate the role of 4-aminopyridine (4-AP) on the course of recovery after peripheral nerve traction and/or crush injury. This study aims to test the hypothesis that 4-aminopyridine speeds the often slow and unpredictable recovery after peripheral nerve traction and/or crush injuries.

Timeline

Start
2021-06-05
Primary completion
2027-07
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Dalfampridine Small molecule 10 mg Oral